

Information page for medical professionals is now available.

— Provides professional information about “N-NOSE”. —

HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki Hirotsu (Hereinafter referred to as “HIROTSU”)), has launched an "Information for Medical Professionals" page with specialized information on the N-NOSE technology in order to promote a better understanding of the N-NOSE nematode cancer test.

Thanks to your support, more than 500,000 people have used the "N-NOSE" nematode cancer test since its launch in 2020, and more than 2,000 companies have introduced the test. Along with the expansion of the service, we have received requests from many people, including medical professionals, for a more detailed understanding of the "N-NOSE" technology. In response, we have decided to open an information page exclusively for medical professionals as a place to provide further information.

<https://hbio.jp/medical/>

This page for medical professionals provides information to understand the performance of the test, such as sensitivity, specificity, and positive predictive value, as well as abstracts of basic and clinical research on N-NOSE, summaries of major research papers, and information on the practical application of N-NOSE.

We will continue to focus on research and development to make the world a better place for early detection of cancer, and will continuously provide information to our customers, medical professionals, and all other stakeholders.

■ About HIROTSU Bio Science

We as HIROTSU aim to protect the health and future security of people through research, development, and practical application of unique technology that utilize the capabilities of living organisms. Established in 2016, N-NOSE was put into practical use thanks to our researchers' abundance of ideas and tireless efforts. Despite the importance of extending

healthy life expectancy being emphasized, it is said that one in every two people will be diagnosed with cancer in this age of 100-year life expectancy. We strive to contribute to solving these social issues with our groundbreaking “bio-diagnoses” technology that utilizes the power of nematodes.

Company Name : HIROTSU Bio Science Inc.
Headquarters : 22F New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo
Representative : Takaaki Hirotsu, CEO
Date of Establishment: August 2016
Main Service : Research, development, and marketing of cancer screenings using nematodes and nematode olfactory sensors
Official Website : <https://hbio.jp/en/>

■ About “N-NOSE”

A primary screening test for cancer that utilizes the highly accurate detection of cancer-specific odors in human urine by the nematode *C. elegans*, which has a very good sense of smell. By simply submitting urine, the test is simple, inexpensive, highly accurate, and provides a whole-body comprehensive examination of early-stage cancer risk.

Official Service Website: <https://lp.n-nose.com/>

■ About “N-NOSE plus Pancreas”

N-NOSE's next-generation "Cancer Type Specific Test". This test uses a "special nematode" genetically engineered from the nematode *C. elegans* that specifically reacts only to the smell of pancreatic cancer. This "special nematode" has a high ability to distinguish between pancreatic cancer and other cancers, enabling non-invasive detection of early-stage pancreatic cancer.

Official Service Website: <https://lp.n-nose.com/suizou/>

■ About “N-NOSE Animals”

“N-NOSE Dogs” and “N-NOSE Cats” developed based on the N-NOSE technology. Up until now, there has not been an easily accessible cancer screening test for pets. Just like N-NOSE for humans, starting in 2023, an easy cancer risk screening only requiring urine for both cats and dogs has been made available due to this product.

Official Service Website: <https://lp.n-nose.com/animal/>

Press Contact

HIROTSU Bio Science PR

E-mail : press@hbio.jp